Insights

Strong Funding Backing Affinia Therapeutics has secured $40 million in Series C funding led by New Enterprise Associates, indicating strong investor confidence and providing substantial financial resources to support its research and development efforts. This funding enables the company to expand its pipeline, invest in advanced manufacturing, and accelerate clinical trials, creating multiple opportunities for partnerships and service collaborations.

Focus on High-Impact Diseases The company's targeted approach toward gene therapies for cardiovascular and neurological diseases presents a significant sales opportunity, especially as science advances to identify new relevant genes. Businesses providing therapeutic delivery solutions, specialized manufacturing, or diagnostic tools for these targeted tissues could find strategic collaboration prospects with Affinia.

Innovation in Delivery Technology Re-engineering AAV9 vectors and developing proprietary capsids positions Affinia as a leader in gene delivery innovation. Companies offering vector manufacturing, capsid design, or related bioengineering services can explore partnerships to support Affinia's development pipeline and enhance its therapeutic capabilities.

Leadership and Talent Growth Recent hires of key executives in operations, medical, and transformation roles indicate active company growth and readiness to scale activities. Technology providers, HR consulting firms, and biotech service providers specializing in organizational scaling and talent management could offer valuable solutions tailored to support Affinia’s expansion efforts.

Strategic Partnerships and Collaborations Affinia’s partnership with Forge Biologics for GMP manufacturing and its ongoing participation in prominent industry conferences show its openness to external collaborations. Suppliers of manufacturing, clinical trial services, or regulatory consulting may find valuable opportunities to engage with a company poised for rapid growth in the gene therapy sector.

Affinia Therapeutics Tech Stack

Affinia Therapeutics uses 8 technology products and services including Open Graph, oEmbed, WooCommerce, and more. Explore Affinia Therapeutics's tech stack below.

  • Open Graph
    Content Management System
  • oEmbed
    Dev Tools
  • WooCommerce
    E-commerce
  • NetSuite
    E-commerce
  • Microsoft Excel
    Editors
  • Microsoft 365
    Email
  • GoDaddy
    Web Hosting
  • Magnific Popup
    Web Tools And Plugins

Media & News

Affinia Therapeutics's Email Address Formats

Affinia Therapeutics uses at least 1 format(s):
Affinia Therapeutics Email FormatsExamplePercentage
FLast@affiniatx.comJDoe@affiniatx.com
92%
F-Last@affiniatx.comJ-Doe@affiniatx.com
5%
FMLast@affiniatx.comJMDoe@affiniatx.com
2%
FMiddleLast@affiniatx.comJMichaelDoe@affiniatx.com
1%

Frequently Asked Questions

Where is Affinia Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Affinia Therapeutics's main headquarters is located at 43 Foundry Suite 120 Waltham, Massachusetts 02453 United States. The company has employees across 1 continents, including North America.

What is Affinia Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Affinia Therapeutics is a publicly traded company; the company's stock symbol is AFTX.

What is Affinia Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Affinia Therapeutics's official website is affiniatx.com and has social profiles on LinkedInCrunchbase.

What is Affinia Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Affinia Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Affinia Therapeutics have currently?

Minus sign iconPlus sign icon
As of March 2026, Affinia Therapeutics has approximately 42 employees across 1 continents, including North America. Key team members include Chief Executive Officer: R. M.Chief Scientific Officer: C. A.Chief Development Officer: L. R.. Explore Affinia Therapeutics's employee directory with LeadIQ.

What industry does Affinia Therapeutics belong to?

Minus sign iconPlus sign icon
Affinia Therapeutics operates in the Biotechnology Research industry.

What technology does Affinia Therapeutics use?

Minus sign iconPlus sign icon
Affinia Therapeutics's tech stack includes Open GraphoEmbedWooCommerceNetSuiteMicrosoft ExcelMicrosoft 365GoDaddyMagnific Popup.

What is Affinia Therapeutics's email format?

Minus sign iconPlus sign icon
Affinia Therapeutics's email format typically follows the pattern of FLast@affiniatx.com. Find more Affinia Therapeutics email formats with LeadIQ.

How much funding has Affinia Therapeutics raised to date?

Minus sign iconPlus sign icon
As of March 2026, Affinia Therapeutics has raised $40M in funding. The last funding round occurred on Oct 07, 2025 for $40M.

When was Affinia Therapeutics founded?

Minus sign iconPlus sign icon
Affinia Therapeutics was founded in 2019.

Affinia Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

We are a team with decades of proven success in translating science from bench to bedside across many companies and medicines, in gene therapy and beyond. We are driven by a purpose: to make a lasting positive impact in the lives of people affected by devastating rare and prevalent diseases where the genetic cause is understood.

Our thesis is simple and our vision, clear: gene therapies have an immense potential to cure many diseases with a one-time dose, but they are limited by current delivery methods for the genetic payload. We formed Affinia Therapeutics to singularly focus on creating innovations that can expand the reach of gene therapies to more prevalent diseases. We're re-engineering adeno-associated virus serotype 9 (AAV9), a gene therapy delivery method that has shown promise but only in a small number of diseases. 

Our initial focus is on diseases of the heart and the nervous system, where we foresee a generational change in the treatment paradigm similar to what has happened in the treatment of cancers. This is because advances in science are identifying new genes associated with diseases of the heart and the nervous system, making a compelling case for genetic medicines. The heart and nervous system are also tissues where targeted delivery of the therapeutic genetic payload is currently inadequate. Our ART platform gives us an advantage to develop first-in-class or best-in-class product candidates.

As an early team member you will play a key role in setting our culture and values. You will be working alongside the founding management team who have a track record of success in the industry. The pace of work is dynamic, fast and fun. 

Our site includes:  State of the Art lab space & Equipment-
Healthy Cafe, Outdoor Patio, State of the Art Gym/Yoga Studio, Lounge ( Pool Table/ Golf Simulator ), Free/Plentiful Parking and More!

Join Us!

Section iconCompany Overview

Headquarters
43 Foundry Suite 120 Waltham, Massachusetts 02453 United States
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
AFTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
11-50

Section iconFunding & Financials

  • $40M

    Affinia Therapeutics has raised a total of $40M of funding over 3 rounds. Their latest funding round was raised on Oct 07, 2025 in the amount of $40M.

  • $10M$25M

    Affinia Therapeutics's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $40M

    Affinia Therapeutics has raised a total of $40M of funding over 3 rounds. Their latest funding round was raised on Oct 07, 2025 in the amount of $40M.

  • $10M$25M

    Affinia Therapeutics's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.